Physician profile
Daniel S Murtagh
NPI 1548265721
$1,068.64
in general payments reported to CMS, 2019-2025
20 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $70.93 · 2021: $140 · 2022: $247 · 2023: $266 · 2024: $14.13 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $230.87 | 2021-2022 | |
| Neotract INC. | $176.51 | 2019-2020 | |
| Boston Scientific Corporation | $99.94 | 2019-2023 | Ams 700 Cxr Rte Kit |
| Astellas Pharma US INC | $89.06 | 2019-2021 | |
| C. R. Bard, INC. & Subsidiaries | $79.60 | 2023 | Bard Urinary Drainage Bag |
| Teleflex LLC | $79.25 | 2023 | Urolift |
| Immunitybio, INC. | $51.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $31.88 | 2025 | Lynparza |
| Allergan, INC. | $24.92 | 2021 | |
| Myovant Sciences INC. | $24.50 | 2021 | |
| Novo Nordisk INC | $23.39 | 2025 | Rivfloza |
| Ferring Pharmaceuticals INC. | $21.12 | 2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $20.02 | 2022 | |
| Progenics Pharmaceuticals, INC. | $19.54 | 2023 | Pylarify |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $16.41 | 2021 | |
| Blue Earth Diagnostics | $14.13 | 2024 | |
| Dendreon Pharmaceuticals LLC | $12.24 | 2019 | |
| Pfizer INC. | $11.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Murtagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.